Abstract
Revealing unknown cues that regulate oligodendrocyte progenitor cell (OPC) function in remyelination is important to optimise the development of regenerative therapies for multiple sclerosis (MS). Platelets are present in chronic non-remyelinated lesions of MS and an increase in circulating platelets has been described in experimental autoimmune encephalomyelitis (EAE) mice, an animal model for MS. However, the contribution of platelets to remyelination remains unexplored. Here we show platelet aggregation in proximity to OPCs in areas of experimental demyelination. Partial depletion of circulating platelets impaired OPC differentiation and remyelination, without altering blood-brain barrier stability and neuroinflammation. Transient exposure to platelets enhanced OPC differentiation in vitro, whereas sustained exposure suppressed this effect. In a mouse model of thrombocytosis (CALRHET), there was a sustained increase in platelet aggregation together with a reduction of newly-generated oligodendrocytes following toxin-induced demyelination. These findings reveal a complex bimodal contribution of platelet to remyelination and provide insights into remyelination failure in MS.
eLife assessment
This important study aims to understand how the regulation of oligodendrocyte progenitor cell (OPC) remyelination and function contributes to the treatment of multiple sclerosis. The authors provide convincing evidence for the platelets mediating OPC differentiation and remyelination. This work will be of interest to several disciplines.
Significance of findings
important: Findings that have theoretical or practical implications beyond a single subfield
- landmark
- fundamental
- important
- valuable
- useful
Strength of evidence
convincing: Appropriate and validated methodology in line with current state-of-the-art
- exceptional
- compelling
- convincing
- solid
- incomplete
- inadequate
During the peer-review process the editor and reviewers write an eLife assessment that summarises the significance of the findings reported in the article (on a scale ranging from landmark to useful) and the strength of the evidence (on a scale ranging from exceptional to inadequate). Learn more about eLife assessments
Introduction
In the central nervous system (CNS), remyelination by newly generated oligodendrocytes is largely mediated by the differentiation of oligodendrocyte progenitor cells (OPCs). In response to demyelination, OPCs proliferate, migrate, and differentiate into remyelinating oligodendrocytes (Franklin & ffrench-Constant, 2008). Although remyelination represents a robust regenerative response to demyelination, it fails during the progress of multiple sclerosis (MS), a CNS autoimmune demyelinating disease (Noseworthy et al., 2000). Unravelling the mechanisms that govern remyelination is essential to our understanding of why this important regenerative process fails in MS, as well as in guiding the development of regenerative therapies.
Platelets are small, anucleate cells essential for haemostatic plug formation (Semple et al., 2011). Platelets also display tissue-regenerative properties (Nurden, 2011). Several growth factors known to modulate OPCs’ responses to demyelination, such as PDGF and FGF2 (Woodruff et al., 2004; Murtie et al., 2005; Zhou et al., 2006; Clemente et al., 2011; Hiratsuka et al., 2019), are stored in platelets (Chen et al., 2012; Lohmann et al., 2012; Schallmoser & Strunk, 2013; Warnke et al., 2013). We have previously shown that platelet lysate increases neural stem / progenitor cells (NSPCs) survival, an alternative but infrequent cellular source for mature oligodendrocytes (Kazanis et al., 2015). Although this evidence argues in favour of a beneficial contribution of platelets to remyelination, other studies suggest a detrimental role. CD41-expressing platelets and platelet-contained molecules are found in non-remyelinated MS lesions (Lock et al., 2002; Han et al., 2008; Langer et al., 2012; Simon, 2012; Steinman, 2012). Moreover, MS patients show increased levels of circulating platelet microparticles (PMPs) (Marcos-Ramiro et al., 2014) and the number of PMPs are indicative of the clinical status of the disease (Saenz-Cuesta et al., 2014). Additionally, MS patients display high plasma levels of platelet-specific factors such as, P-selectin and PF4 that correlate with disease course and severity, respectively (Cananzi et al., 1987; Kuenz et al., 2005). In the animal model for MS, experimental autoimmune encephalomyelitis (EAE), platelet numbers within CNS increase (Sonia D’Souza et al., 2018). When platelets were immunodepleted before clinical onset, EAE severity is decreased (Langer et al., 2012; Kocovski et al., 2019). Here we ask whether circulating platelets regulate OPC function and how this impacts remyelination.
Results
Circulating platelets transiently accumulate in response to demyelination and accumulate in close proximity to OPCs
We first assessed the distribution of platelets during remyelination. We created lysolecithin (LPC)-induced demyelinating lesions in the spinal cord white matter of wild type (WT) mice and collected tissue sections at 1-, 3-, 5-, 7-, 10 and 14-days post-lesion (dpl). We observed CD41+ platelet aggregates within and around the lesion early after demyelination (3 dpl) (p-value < 0.01) (Figure 1A and B). However, this was transient as platelet aggregates subsequently decreased until no aggregates were detected at 14 dpl (Figure 1A and B). To assess whether platelet recruitment was specific to demyelination we injected PBS containing DAPI directly into the spinal cord. No signs of demyelination were observed under these conditions and platelet aggregation was minimal at 1- and 3-days post-PBS injection (Figure 1C). We next evaluated the localization of platelets within the lesion. Large platelet aggregates were found within the blood vessels and within the tissue parenchyma at 5 dpl (Figure 1D). Platelets often localised with Olig2+ cells around blood vessels, a scaffold used by OPCs for migration (Tsai et al., 2016) (Figure 1D).
Depletion of circulating platelets alters OPC differentiation and remyelination in vivo
To investigate whether circulating platelets modulate OPC function in vivo, we used a platelet depletion model (Figure 2A). LPC-induced focal demyelinating lesions were performed in WT mice followed by the administration of anti-CD42b at 3 dpl and every second day to prevent further platelet recruitment (Morodomi et al., 2020; de Sousa et al., 2023). We first confirmed that this depletion strategy leads to decreased numbers of recruited platelets, with no accumulation in the lesion (p-value < 0.05) (Figure 2B). At 7 dpl, there was no difference in the number of Olig2+ cells within the lesion between the platelet depleted and untreated group (Figure 2C, upper panels, and D), indicating that platelets do not alter OPC recruitment in response to demyelination. Through the detection of CC1 expression, a marker that identifies mature oligodendrocytes (Figure 2C, lower panels), we found that platelet depletion significantly decreased the number and percentage of Olig2+/CC1+ cells compared to untreated mice (p-value ≤ 0.05) (Figure 2E and 2F), indicating that platelet depletion impairs OPC differentiation. Consistently, at 14 dpl we observed a significant decrease in the extent of remyelination (Figure 2G and 2H) and the percentage of remyelinated axons compared to untreated animals (p-value < 0.05) (Figure 2I). Previous studies have shown that decreasing the number of circulating platelets increases blood vessel leakiness (Cloutier et al., 2012; Gupta et al., 2020). To assess whether impaired OPC differentiation might be due to fibrinogen extravasation (Petersen et al., 2017) or enhanced demyelination due to neutrophil infiltration (Ruther et al., 2017), we evaluated their presence within the lesion parenchyma after platelet depletion. There were no significant differences between neutrophil (Supplementary Figure 1A and B) and fibrinogen extravasation (Supplementary Figure 1C and D) after platelet depletion at 7 dpl, indicating that remyelination impairment likely derives from low numbers of circulating platelets rather than increased vascular leakiness.
Depletion of circulating platelets does not alter macrophage/microglia numbers and polarization during remyelination
Blood-borne macrophages and CNS-resident microglia are essential for OPC differentiation during remyelination (Kotter et al., 2006; Miron et al., 2013). As platelets regulate macrophage function in neuroinflammation (Langer & Chavakis, 2013; Carestia et al., 2019; Rolfes et al., 2020) and since platelets are located near macrophages/microglia upon demyelination (Supplementary Figure 2A), we evaluated whether platelet depletion affects these cell populations (Supplementary Figure 2B). At 10 dpl, platelet depletion did not alter the total number of IBA-1+ (Supplementary Figure 2C), pro-inflammatory IBA-1+/CD16/32+ (Supplementary Figure 2D) or anti-inflammatory IBA-1+/Arg-1+ (Supplementary Figure 2E) macrophages/microglia present within the remyelinating lesion. Furthermore, platelet depletion did not influence macrophage/microglia phagocytic activity as no difference in myelin debris clearance, detected by Oil-red O, was observed (Supplementary Figure 2F and G). Therefore, circulating platelets likely impact OPC differentiation without interfering with macrophage/microglia numbers/polarization during remyelination.
Transient in vitro exposure to platelets enhances OPC differentiation
To confirm whether transient platelet exposure directly enhances OPC differentiation, OPCs were briefly exposed to washed platelets (WP) for 3 days (pulse) and differentiation was assessed 3 days after WP withdrawal. OPCs briefly exposed to 10% WP exhibited a significant increase in the percentage of Olig2+/MBP+ mature oligodendrocytes compared to the vehicle treated control (p-value < 0.0001) (Figure 3A and B), indicating that transient contact to platelets directly promotes OPC differentiation. Similar increases in the proportion of Olig2+/MBP+ mature oligodendrocytes were observed when OPCs were transiently exposed to 1% platelet lysate (PL) compared to vehicle-treated control, indicating that this effect is, at least in part, mediated through platelet-contained factors and direct cell-cell contact is not essential (p-value < 0.05) (Figure 3C - D).
Sustained increase in circulating platelets hampers OPC differentiation during remyelination
Chronically-demyelinated MS lesions have been reported to contain a substantial number of platelets and their derived molecules (Lock et al., 2002; Han et al., 2008; Langer et al., 2012; Simon, 2012; Steinman, 2012). To explore the effects of prolonged platelet exposure on OPC differentiation we conducted experiments with sustained exposure to 10% WP. Contrary to the 3-day pulse-based exposure, 6-days of sustained exposure to 10% WP suppressed the ability of platelets to enhance OPC differentiation (Figure 3A and B). Similar findings were observed upon 9-days of sustained exposure to 1% PL (Figure 3E and F), indicating effects mediated by platelet-contained factors. To test whether this effect is reversible, PL was withdrawn upon 6 days of sustained exposure, and OPC differentiation was evaluated 3 days later. Interestingly, PL withdrawal rescued the capability of platelets to enhance OPC differentiation when compared to the vehicle treated control and the sustained condition (p-value < 0.0006) (Figure 3E - F).
To assess whether a permanent increase of circulating platelets may hamper OPC differentiation during remyelination, we used a conditional mouse knock-in model carrying a mutation within the calreticulin gene in a heterozygous fashion controlled by the VaV hematopoietic promoter, resulting in sustained thrombocytosis (2 to 3 times more circulating platelets) without alterations in other cell lineages (Li et al., 2018). We induced a demyelinating lesion by LPC injection in the spinal cord white matter of CALRHET mice and evaluated platelet recruitment and OPC differentiation. As expected, CALRHET mice showed increased levels of circulating platelets (p-value < 0.01) (Figure 4B) as well as a higher number of recruited platelets into the lesion (p-value < 0.05) (Figure 4A and C). At 10 dpl, CALR mice displayed a reduced number of mature Olig2+/CC1+ oligodendrocytes (Figure 4D and F) and a significant decrease in the percentage of differentiated OPCs (p-value < 0.05) (Figure 4G) compared to WT mice, without alterations in the total number of Olig2+ cells (Figure 4E). Additionally, we observed a negative correlation between the number of circulating platelets in CALRHET mice with the number of mature oligodendrocytes (r= -0.75, p-value < 0.01) (Figure 4H). Similar to the platelet depleted model, effects on OPC differentiation are not mediated by inflammation, as CALRHET mice showed no alterations in macrophage/microglia numbers/polarization during remyelination (Supplementary Figure 2B-E). These findings indicate that sustained exposure to platelets directly hampers OPC differentiation during remyelination.
Discussion
In conclusion, our study reveals that in response to myelin damage platelets transiently accumulate within the vascular niche and locate near OPCs. While transient contact to platelets support OPC differentiation, long lasting exposure to elevated numbers of circulating platelets hampers the generation of oligodendrocytes during remyelination. These findings argue in favour of a beneficial physiological role of platelets in remyelination. However, we also highlight that sustained increased platelet counts, as occurs in MS-related conditions, negatively alter OPC function and contribute to remyelination failure in MS.
Although there is a need to reveal the underlying mechanism(s) by which platelets exert a bimodal action on OPC differentiation, our findings indicate that platelet-contained factors contribute to this effect. This study shows that the regeneration of oligodendrocytes rests on the transient vs sustained presence of platelets within demyelinated lesions. Platelet accumulation in MS lesions may result from blood-brain barrier damage (Broman, 1964; Zlokovic, 2008) and/or a clearance failure, but changes in their adhesiveness (Sanders et al., 1968) and hyperactivity observed during MS (Sheremata et al., 2008) may contribute to such scenario. Strategies that restore platelet function, spatially and temporally, represent a future step for developing regenerative therapies in MS.
Materials and methods
Animals
All animal work at University of Cambridge complied with the requirements and regulations of the United Kingdom Home Office (Project Licenses PCOCOF291 and P667BD734). All the experiments at Universidad Austral de Chile were conducted in agreement with the Chilean Government’s Manual of Bioethics and Biosafety (CONICYT: The Chilean Commission of Scientific and Technological Research, Santiago, Chile) and according to the guidelines established by the Animal Protection Committee of the Universidad Austral de Chile (UACh). The animal study was reviewed and approved by the Comité Institucional de Cuidado y Uso de Animales (CICUA)-UACh (Report Number # 394/2020). All the experiments at University of Helsinki followed the guidelines posed by the Academy of Finland and the University of Helsinki on research ethics and integrity (under Internal License KEK23-022) and accordingly to the National Animal Ethics Committee of Finland (ELLA). Mice and rats had access to food and water ad libitum and were exposed to a 12-hour light cycle.
Human subjects
Human platelets were obtained from blood samples of healthy volunteers who signed a consent form before sampling. All procedures were approved by the Comité Ético y Científico del Servicio de Salud de Valdivia (CEC-SVS) (ORD N° 510) to carry experiments at Universidad Austral de Chile and by the Ethical Committee of the University of Cambridge to perform experiments at this institution. The blood donors at Cambridge were approved by the human biology research ethics committee (reference number: HBREC.2018.13.).
Focal demyelination lesions
A focal demyelinating lesion was induced in C57BL/6 and CALRHET mice between 2-4 months of age. Animals were anesthetized using Isoflurane/Oxygen (2-2.5%/1000 ml/min O2) and buprenorphine (0.05 mg/kg) was injected subcutaneously immediately before surgery. Local Lysolecithin-driven demyelination in mice was induced as previously described in (Fancy et al., 2009). Briefly, the spinal cord was exposed between two vertebrae of the thoracic column and demyelination was induced by injecting 1uL of 1% lysolecithin (L-lysophosphatidylcholine, Sigma) into the ventral funiculus at a rate of approximately 0.5 µl/min−1. The incision was then sutured, and the animal was left to recover in a thermally controlled chamber. Animals were monitored for 72 hours after surgery. Any signs of pain, dragging of limbs, or weight loss of more than 15% of pre-surgery weight, resulted in cessation of the experiment. Mice were sacrificed at 1, 3, 5, 7, 10, and 14 dpl by transcardial perfusion of 4% PFA or glutaraldehyde under terminal anaesthesia.
Platelet Depletion
For platelet depletion, mice received an intraperitoneal injection (IP) of 0.6µg/g of antiCD42b (Emfret Analytics) (Evans et al., 2021), diluted in saline solution, at 3 dpl, followed by IP injections every 48 hours until the end of the experiment period. The effectiveness of platelet depletion was confirmed by measuring the number of circulating platelets using a VetAnalyzer (scil Vet abc Plus). Mice with a circulating platelet number below 200,000 platelets/uL were considered successfully depleted.
Preparation of washed platelets and platelet lysate
Washed platelets (WP) were prepared as described (Cazenave et al., 2004). Briefly, human blood samples were taken from the median cubital vein and collected in sodium citrate followed by centrifugation for 20 mins at 120x g to separate the red blood cells from the plasma. Plasma was collected and centrifuged at 1400x g to pellet platelets. Plasma was removed without disrupting the platelet pellet. PGI2 and sodium citrate were carefully added, followed by resuspension in Tyrode’s buffer. Platelet number was quantified using a Vet Analyzer and adjusted to a concentration of 1,000,000 platelets/uL. WP were used fresh, meanwhile for the platelet lysate (PL) preparation, the suspension underwent two freeze-thaw overnight cycles. Platelet fragments were then eliminated by centrifugation at 4000x g for 15 minutes and the supernatant was collected and stored at - 20°C.
Primary OPC cultures
Rat OPCs were isolated as described by (Neumann et al., 2019). Cells were then seeded onto glass plates pre-coated with Poly-D-Lysine (PDL) in 24-well plates, with a seeding density of 7,000 cells for differentiation assays and 10,000 cells for proliferation assays. For differentiation conditions, T3 was added to the culture media. All experimental conditions were replicated using two independent technical replicates. OPCs were either subjected to various concentrations of washed platelets (1%, 5%, and 10%) or to 1% of platelet lysate of the final volume.
Histology and Immunofluorescence
After transcardial perfusion with 4% PFA, tissue was post-fixed overnight in 4% PFA at 4°C. After fixation, spinal cords were left in 30% sucrose overnight. Tissue was then embedded in OCT and cut in 15um transverse sections on a Leica Cryostat. Samples were stored at - 80°C until use.
For immunofluorescence staining of tissues, samples were left to thaw for 30 mins and washed with PBS. Samples were blocked for 1 hour, using a blocking solution that contained; 10% horse serum, 1% bovine serum albumin, 0.1% cold fish gelatin, 0.1% Triton X-100, and 0.05% Tween 20, diluted in PBS. After blocking, samples were incubated overnight at 4°C with primary antibody diluted in PBS containing 1% bovine serum albumin, 0.1% cold fish gelatin, and 0.5% Triton X-100. The following primary antibodies were used: rat anti-CD41 (1:200 Abcam), rat anti-CD16/32 (1:200, Santa Cruz), rabbit anti-IBA1 (1:500, WAKO), rat anti-CD31 (1.300 BD Biosciences), rabbit anti-Olig2 (1:200, Abcam), rabbit anti-Ki67 (1:100, Abcam), goat anti-Arg1 (1:200, Santa Cruz), mouse anti-CC1 (1:1000, Calbiochem), rat anti-NIMP-R14 (1:200, Abcam). Samples were washed 3 times for 5mins in PBS. After washing, samples were incubated with secondary antibody and DAPI for 1 hour, diluted in the same solution as the primary antibody. Samples were washed 3 times for 5 mins in PBS. Samples were mounted with Fluromount. All secondary antibodies were diluted 1:500. For imaging of spinal cord tissue, the entire lesion area was imaged for 5 technical replicates.
For immunofluorescence staining of cell cultures, samples were initially washed three times with PBS for 5 mins after fixation. The cells were then blocked with 10% Donkey Serum (DKS) in PBS for 1 hour, followed by incubation with the primary antibody overnight, diluted in the same blocking solution. The following primary antibodies were utilized: Rat Anti-Myelin Basic Protein (MBP; 1:500, Biorad) and Rabbit Anti-Oligodendrocyte transcription factor 2 (Olig2; 1:500, Abcam). The cells were then washed three times with PBS 1x for 5 mins, followed by incubation with secondary antibodies, diluted in the blocking solution, for 1 hour. The cells were washed three more times with PBS 1x for 5 mins.
Images were captured using a Leica SP8 Laser Confocal, a Zeiss LSM 980 Confocal or an Olympus IX81FV1000. For cell culture imaging, 8-10 photos per well were quantified for each well using an automated macro in ImageJ/Fiji. For in-vivo imaging, 3-5 photos were quantified per animal by a blinded observer. For tissue image analysis and 3D reconstruction of platelet localisation, ImageJ/Fiji (version 2.1.0/1.53 h) and Imaris (Bitplane, version 9.3.1, and 9.9.0) were used.
Oil-red O Staining
To analyse myelin debris clearance, tissue sections were stained with Oil-red O as previously described by (Kotter et al., 2005). Briefly, sections were stained with freshly prepared Oil-red O and incubated at 37 degrees for 30 mins. Slides were washed and mounted using an aqueous mounting medium. Image J was used to threshold and quantify Oil-red O images.
Remyelination Ranking Analysis
For remyelination studies, tissue was fixed with 4% glutaraldehyde and embedded in resin. Semi-thin sections of the lesion were cut and stained with Toluidine Blue. Three blinded observers ranked the level of remyelination for each biological individual, giving the most remyelinated individual the highest score, and the individual with the lowest degree of remyelination the lowest. The average for each animal was calculated from the three independent observer rankings.
Statistical Analysis
Statistical analysis was performed using GraphPad Prism 8. The distribution of data were first tested using a Shapiro-Wilks test. One-way ANOVA or a Kruskal Wallis one-way analysis, with the corresponding post-hoc test, were used to compared multiple groups, and a Mann-Whiteney U-test or an unpaired t-test was used to compare between groups. P-values were represented as *≤0.05, **≤0.01, ***≤0.001, ***≤0.0001.
Funding
Authors would like to thank the funding support from Agencia Nacional de Investigación y Desarrollo (ANID, Chile)-FONDECYT Program Regular Grant Number 1201706 and 1161787 (both to F.J.R.), ANID-PCI Program Grant N° REDES170233 (to F.J.R.) and N° REDES180139 (to M.A.C), ANID-National Doctoral Fellowship N° 21170732 (to A.R.P) and N° 21211727 (to C.R.R). In addition, the authors would like to thank the PROFI 6 N° 336234 of the Research Council of Finland.
Supporting information
Acknowledgements
Special acknowledgments to the Comité Ético y Científico del Servicio de Salud de Valdivia (CEC-SVS) for ethical guidance and approval (ORD N° 510). The authors would like to thank the Laboratory of Chronobiology, UACh (led by Dr. Claudia Torres-Farfán) for supporting animal experimentation. We would also like to thank Dr. Alerie Guzman de la Fuente for the Fiji/ImageJ macro for in-vitro quantification.
Disclosure statement
The authors declare that there are no conflicts of interest.
Note
This reviewed preprint has been updated to use the correct text; previously, a version prior to the one reviewed was presented here.
References
- Blood-Brain Barrier Damage in Multiple Sclerosis Supravital Test-ObservationsActa Neurol Scand Suppl 40:21–14
- Relevance of platelet factor four (PF4) plasma levels in multiple sclerosisActa Neurol Scand 76:79–85
- Platelets Promote Macrophage Polarization toward Pro-inflammatory Phenotype and Increase Survival of Septic MiceCell reports 28:896–908
- Preparation of washed platelet suspensions from human and rodent bloodMethods in molecular biology 272:13–28
- The effects of human platelet lysate on dental pulp stem cells derived from impacted human third molarsBiomaterials 33:5023–5035
- FGF-2 and Anosmin-1 are selectively expressed in different types of multiple sclerosis lesionsThe Journal of neuroscience : the official journal of the Society for Neuroscience 31:14899–14909
- Platelets can enhance vascular permeabilityBlood 120:1334–1343
- Immune-mediated platelet depletion augments Alzheimer’s disease neuropathological hallmarks in APP-PS1 miceAging (Albany NY 15:630–649
- Transfer to the clinic: refining forward programming of hPSCs to megakaryocytes for platelet production in bioreactorsBlood Adv 5:1977–1990
- Dysregulation of the Wnt pathway inhibits timely myelination and remyelination in the mammalian CNSGenes Dev 23:1571–1585
- Remyelination in the CNS: from biology to therapyNature reviews. Neuroscience 9:839–855
- Hemostasis vs. homeostasis: Platelets are essential for preserving vascular barrier function in the absence of injury or inflammationProc Natl Acad Sci U S A 117:24316–24325
- Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targetsNature 451:1076–1081
- VEGF- and PDGF-dependent proliferation of oligodendrocyte progenitor cells in the medulla oblongata after LPC-induced focal demyelinationJournal of neuroimmunology 332:176–186
- Lesion-induced accumulation of platelets promotes survival of adult neural stem / progenitor cellsExperimental neurology 269:75–89
- Platelet Depletion is Effective in Ameliorating Anxiety-Like Behavior and Reducing the Pro-Inflammatory Environment in the Hippocampus in Murine Experimental Autoimmune EncephalomyelitisJ Clin Med 8
- Myelin impairs CNS remyelination by inhibiting oligodendrocyte precursor cell differentiationThe Journal of neuroscience : the official journal of the Society for Neuroscience 26:328–332
- Macrophage-depletion induced impairment of experimental CNS remyelination is associated with a reduced oligodendrocyte progenitor cell response and altered growth factor expressionNeurobiology of disease 18:166–175
- Plasma levels of soluble adhesion molecules sPECAM-1, sP-selectin and sE-selectin are associated with relapsing-remitting disease course of multiple sclerosisJournal of neuroimmunology 167:143–149
- Platelets and neurovascular inflammationThrombosis and haemostasis 110
- Platelets contribute to the pathogenesis of experimental autoimmune encephalomyelitisCirculation research 110:1202–1210
- Mutant calreticulin knockin mice develop thrombocytosis and myelofibrosis without a stem cell self-renewal advantageBlood 131:649–661
- Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitisNature medicine 8:500–508
- Donor age of human platelet lysate affects proliferation and differentiation of mesenchymal stem cellsPloS one 7
- Microparticles in multiple sclerosis and clinically isolated syndrome: effect on endothelial barrier functionBMC Neurosci 15
- M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelinationNature neuroscience 16:1211–1218
- Mechanisms of anti-GPIbalpha antibody-induced thrombocytopenia in miceBlood 135:2292–2301
- PDGF and FGF2 pathways regulate distinct oligodendrocyte lineage responses in experimental demyelination with spontaneous remyelinationNeurobiology of disease 19:171–182
- Metformin Restores CNS Remyelination Capacity by Rejuvenating Aged Stem CellsCell stem cell 25:473–485
- Multiple sclerosisThe New England journal of medicine 343:938–952
- Platelets, inflammation and tissue regenerationThrombosis and haemostasis 105:S13–33
- Fibrinogen Activates BMP Signaling in Oligodendrocyte Progenitor Cells and Inhibits Remyelination after Vascular DamageNeuron 96:1003–1012
- Platelets Fuel the Inflammasome Activation of Innate Immune CellsCell reports 31
- Combination of cuprizone and experimental autoimmune encephalomyelitis to study inflammatory brain lesion formation and progressionGlia 65:1900–1913
- Circulating microparticles reflect treatment effects and clinical status in multiple sclerosisBiomark Med 8:653–661
- Further studies on platelet adhesiveness and serum cholesteryl linoleate levels in multiple sclerosisJ Neurol Neurosurg Psychiatry 31:321–325
- Generation of a pool of human platelet lysate and efficient use in cell cultureMethods in molecular biology 946:349–362
- Platelets and the immune continuumNature reviews. Immunology 11:264–274
- Evidence of platelet activation in multiple sclerosisJournal of neuroinflammation 5
- Inflammation and vascular injury: basic discovery to drug developmentCirculation journal : official journal of the Japanese Circulation Society 76:1811–1818
- Platelets Drive Inflammation and Target Gray Matter and the Retina in Autoimmune-Mediated EncephalomyelitisJournal of neuropathology and experimental neurology 77:567–576
- Platelets provide a bounty of potential targets for therapy in multiple sclerosisCirculation research 110:1157–1158
- Oligodendrocyte precursors migrate along vasculature in the developing nervous systemScience 351:379–384
- A clinically-feasible protocol for using human platelet lysate and mesenchymal stem cells in regenerative therapiesJournal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery 41:153–161
- Platelet-derived growth factor regulates oligodendrocyte progenitor numbers in adult CNS and their response following CNS demyelinationMolecular and Cellular Neuroscience 25:252–262
- Retroviral lineage analysis of fibroblast growth factor receptor signaling in FGF2 inhibition of oligodendrocyte progenitor differentiationGlia 54:578–590
- The blood-brain barrier in health and chronic neurodegenerative disordersNeuron 57:178–201
Article and author information
Author information
Version history
- Sent for peer review:
- Preprint posted:
- Reviewed Preprint version 1:
- Reviewed Preprint version 2:
- Version of Record published:
Copyright
© 2023, Philp et al.
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
- views
- 833
- downloads
- 88
- citations
- 0
Views, downloads and citations are aggregated across all versions of this paper published by eLife.